Skip to content

The Oncology Institute, Inc. TOI Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

McKesson logo
McKessonMCK
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
Summit Therapeutics logo
Summit TherapeuticsSMMT
Exelixis logo
ExelixisEXEL
Incyte logo
IncyteINCY
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%
Free cash flow-$3.3M+38.7%

Valuation

See full
Market cap$511.91M+133%
Enterprise value$586.58M+108%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Reported directly by The Oncology Institute, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s preferred stock, shares authorized?
The Oncology Institute, Inc. (TOI) reported preferred stock, shares authorized of $10M in Q1 2026.
How has The Oncology Institute, Inc.'s preferred stock, shares authorized changed year-over-year?
The Oncology Institute, Inc.'s preferred stock, shares authorized decreased by 0.0% year-over-year, from $10M to $10M.
What is the long-term trend for The Oncology Institute, Inc.'s preferred stock, shares authorized?
Over 4 years (2021 to 2025), The Oncology Institute, Inc.'s preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $10M to $10M.